The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 38 | — | 20.1x | Near average | |
Growth | 37 | -100.0% | 5.6% | Near average | |
Quality | 52 | 957.6% | 7.6% | Near average | |
Safety | 27 | 0.5x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Inovio Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Inovio Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The future outlook for Inovio Pharmaceuticals stock has witnessed a sharp decline, as the average price target dropped from $18.5 to $2.5, representing a decrease of 86.49%. This radical adjustment reflects a comprehensive reassessment by analysts of the stock's market value, despite the number of following analysts remaining stable at one analyst in recent data, indicating a high concentration in estimates and an absence of statistical Dispersion currently.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.